Physician profile
Alexander Malayev
NPI 1992757645
$3,399.60
in general payments reported to CMS, 2019-2025
24 companies · $89.10 in 2025
The $89.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $156 · 2021: $464 · 2022: $1,121 · 2023: $824 · 2024: $169 · 2025: $89.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $996.78 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $617.99 | 2019-2024 | Repatha |
| Abbvie INC. | $441.49 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $257.29 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $136.32 | 2023 | Xarelto |
| Genentech USA, INC. | $125.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.95 | 2022-2023 | Breztri |
| Glaxosmithkline, LLC. | $105.26 | 2020-2023 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.17 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $78.21 | 2019-2020 | |
| Lilly USA, LLC | $60.35 | 2022-2024 | Jardiance |
| Pfizer INC. | $33.91 | 2023 | |
| Horizon Therapeutics Plc | $20.96 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.75 | 2021 | |
| Sumitomo Pharma America, INC. | $18.84 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.95 | 2022 | |
| Alfasigma USA, INC. | $14.69 | 2022 | |
| Axsome Therapeutics, INC. | $13.67 | 2023 | Auvelity |
| Bioventus LLC | $13.52 | 2021 | |
| Amarin Pharma, INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Malayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.